India, June 16 -- Sarepta Therapeutics, Inc. (SRPT) shares collapsed 45.30 percent, or $16.40, to $19.78 on Monday after reports of a possible death of a recipient in the company's second gene therapy clinical trial stated by Investor's Business Daily. The news has sparked significant investor concern over the safety profile of the treatment. The stock opened at $21.26 and has fluctuated between $18.30 and $21.55 during the session on the Nasdaq. Volume has spiked to 25.96 million shares, sharply higher than the average of 3.90 million. The 52-week range for the stock is $18.30 to $173.25.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....